Approaches to male hypogonadism in primary care.
Kristi L Lawrence, Felicia Stewart, Brandi M Larson
PMID 28085783WHAT IT FOUND
Guidelines disagree on who to screen, testosterone thresholds, repeat labs, and prostate checks.
Before testosterone treatment, confirm symptoms and low morning levels, repeat testing, and review prostate and cardiovascular risks.
Key findings
01No guideline supports universal screening of adult men, and they differ on which chronic conditions warrant testing.
02Several guideline sources recommend treating symptomatic men when total testosterone is under 8 nmol/L, but thresholds for further evaluation vary.
03Prostate and cardiovascular safety are uncertain: guidelines lack a consistent DRE/PSA rule, and current evidence does not show increased cardiovascular risk, though FDA labeling warns of possible myocardial infarction and stroke.
STILL TO COME
How it was doneWhat they foundWhat it means for RNs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
This is a guideline comparison, not a trial of testosterone therapy, so it cannot tell you whether treatment improves symptoms or outcomes. The reviewed guidelines disagree on screening, diagnostic thresholds, repeat testing timing, and prostate checks, so it cannot provide a uniform protocol. The paper says evidence on prostate cancer and cardiovascular risk with testosterone therapy is insufficient or not definitive. It focuses on primary care nurse practitioners, so it may not address specialist management or all patient groups.
The easy way to misread this
Do not treat this as proof that testosterone therapy improves symptoms or is safe for everyone. It compares guideline recommendations and says evidence is not definitive for screening, diagnosis, prostate risk, and cardiovascular risk.